| abstract |
This disclosure is particularly directed to antibodies that bind to C5a, or antigen-binding fragments thereof, and at least one of the following: an atypical hemolytic uremic syndrome, an aging-associated visual loss, rheumatoid arthritis, a hemorrhage, severe burn, antiphospholipid syndrome, asthma, Goodpasture ' s syndrome, and chronic obstructive pulmonary disease. ≪ RTI ID = 0.0 > [0002] < / RTI > |